Azmi Nasser, PhD

Extended-Release Viloxazine (SPN-812) 200 mg or 400 mg for the Treatment of ADHD in Children: Topline Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P303)

Background: SPN-812 (extended-release viloxazine) is a structurally distinct, bicyclic, Serotonin Norepinephrine Modulating Agent (SNMA) being developed as a treatment for pediatric atten...

Stefan Schwabe , MD, PhD;

Azmi Nasser , PhD;

Joseph Hull , PhD;

Fatima Chowdhry , MD;

Toyin Adewole , MD, MPH;

Tesfaye Liranso , PhD;

11/22/2019

Extended-Release Viloxazine (SPN-812) 200 mg or 400 mg for the Treatment of ADHD in Adolescents: Topline Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P302)

Background: SPN-812 (extended-release viloxazine) is a structurally distinct, bicyclic, Serotonin Norepinephrine Modulating Agent (SNMA) being developed as a treatment for pediatric atten...

Azmi Nasser , PhD;

Joseph Hull , PhD;

Fatima Chowdhry , MD;

Toyin Adewole , MD, MPH;

Tesfaye Liranso , PhD;

Stefan Schwabe , MD, PhD;

11/22/2019

Extended-Release Viloxazine (SPN-812) 100 mg or 200 mg for the Treatment of ADHD in Children: Topline Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P301)

Background: SPN-812 (extended-release viloxazine) is a structurally distinct, bicyclic, Serotonin Norepinephrine Modulating Agent (SNMA) being developed as a treatment for attention-defic...

Azmi Nasser , PhD;

Joseph Hull , PhD;

Fatima Chowdhry , MD;

Toyin Adewole , MD, MPH;

Tesfaye Liranso , PhD;

Stefan Schwabe , MD, PhD;

11/22/2019

Update on a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating SPN-810 for the Treatment of Impulsive Aggression (IA) in Pediatric Patients with ADHD

Background: Aggression is one of the most common reasons for psychiatric referral in children. The most prevalent subtype of maladaptive aggression is IA – which is reactive, overt, and o...

Azmi Nasser , PhD;

Fatima Chowdhry , MD;

Toyin Adewole , MD, MPH;

Tesfaye Liranso , PhD;

Jiahong Xu , MS, MPH;

Ronald Marcus , MD;

03/01/2019

Viloxazine Extended-Release Capsules (Qelbree®) for Adults with Attention-Deficit/Hyperactivity Disorder: Evaluating the Potential Impact of Caffeine Exposure on Safety Profile

Abstract: Viloxazine ER (viloxazine extended-release capsules, Qelbree®) is a novel, nonstimulant, FDA-approved treatment for adults and children (≥6 yrs) with ADHD. Viloxazine ER inhibit...

Jami Earnest ;

Azmi Nasser , PhD;

01/19/2023

The Impact of Long-Term Treatment with Viloxazine Extended-Release Capsules (Qelbree®) on Executive Function in Adults with Attention-Deficit/Hyperactivity Disorder

Abstract: Viloxazine ER is a novel, nonstimulant, FDA-approved treatment for ADHD in children and adults (≥ 6 years). Viloxazine ER effects on executive function (EF) deficits were evalua...

Azmi Nasser , PhD;

01/19/2023

Interim Analysis of Efficacy During Long-Term Treatment with Viloxazine Extended-Release Capsules (Qelbree®) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Abstract: Viloxazine ER (Qelbree®) is a novel, nonstimulant, FDA-approved treatment for ADHD in pediatric patients (≥6 years) and adults. The efficacy of viloxazine ER was evaluated in 4 ...

Azmi Nasser , PhD;

01/19/2023